AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00137007
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03146689
Drug: Topical NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied four times daily
Trial: NCT01623401
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 FA 200 mg once daily
Trial: NCT02621489
Drug: Humulin kwickpen
RxNorm normalized name: Humulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humulin kwickpen 10U QD at bedtime
Trial: NCT03876886
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
Trial: NCT03727048
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
Trial: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650117
Drug: Duragesic 25 mcg/h + Scotch Duct Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650117
Drug: Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650117
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00650117
Drug: Duragesic 25 mcg/h + Microfoam Tape (3M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT02053142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01201837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly injection
Trial: NCT01691677
Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03436693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily
Trial: NCT04303520
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/m2/d
Trial: NCT00966004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01519557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02666196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02089308
Drug: Test treatment : V0116 transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00657033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
Trial: NCT04626739
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/㎡ for D-3 and D-2
Trial: NCT04339985
Drug: ATx201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT04339985
Drug: ATx201 OINTMENT vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATx201 OINTMENT vehicle
Trial: NCT00003163
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03789578
Drug: NNC0148-0287sema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Trial: NCT01963338
Drug: Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This injection is conducted by needle and syringe in the upper arm (deltoid region).
Trial: NCT00378001
Drug: FSH-IBSA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00152464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Oral drops Route of administration: Oral use
Trial: NCT03823781
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention is an intravenous infusion of milrinone or placebo.
Trial: NCT00260143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01489774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple dose
Trial: NCT01489774
Drug: CJ-12406
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single and multiple dose
Trial: NCT01271348
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib film tablet, 90 mg, q.d.
Trial: NCT01271348
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, q.d.
Trial: NCT04001218
Drug: Injection of hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
Trial: NCT04001218
Drug: Injection of Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
Trial: NCT03785574
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
Trial: NCT02158806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule containing inert bulking agent
Trial: NCT03280511
Drug: PIPAC
RxNorm normalized name: Zagam Respipac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
Trial: NCT03118362
Drug: Plasmalyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Trial: NCT03118362
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Trial: NCT00420199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
Trial: NCT00680901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 pills once daily
Trial: NCT00680901
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1700mg/m2/day in two daily doses
Trial: NCT03821714
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The glucocorticoid group was defined as the use of hydrocortisone alone.
Trial: NCT02219659
Drug: Sedation Protocol with Daily Interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
Trial: NCT02960035
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01330316
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV for 48 weeks
Trial: NCT02219659
Drug: Sedation Protocol Without Daily Interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
Trial: NCT02219659
Drug: Fentanyl Push First
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
Trial: NCT03525548
Drug: VX-445/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Trial: NCT03525548
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received TEZ/IVA orally once daily in the morning.
Trial: NCT03525548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
Trial: NCT03525548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.
Trial: NCT01913535
Drug: CERC-501
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Trial: NCT01913535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days.
Trial: NCT03426202
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 200mg
Trial: NCT01864109
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03769402
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid ph1, 50% concentration solution
Trial: NCT03769402
Drug: Control Test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, xenograft was used to fill infrabony defects without treating bone surface
Trial: NCT02060084
Drug: a probiotic-supplemented group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
Trial: NCT00035048
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00055653
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03680586
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo ultra low-dose radiation
Trial: NCT02227875
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
Trial: NCT05462535
Drug: Amosartan Plus Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amosartan Plus Tab., Once daily administered per the locally approved product information
Trial: NCT00281905
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00281905
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04270071
Drug: Yangxin Shengmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxin Shengmai Granules
Trial: NCT04270071
Drug: Yangxin Shengmai placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
Trial: NCT04016779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily
Trial: NCT02295020
Drug: Standard treatment only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment such as NSAIDs and injections
Trial: NCT01511874
Drug: ELIGARD 22.5mg
RxNorm normalized name: Eligard 22.5mg Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
Trial: NCT01281202
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03015610
Drug: matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
Trial: NCT00978081
Drug: aminolevulinic acid hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergo continuous or fractionated photodynamic therapy.
Trial: NCT01883817
Drug: DHA Omega-3
RxNorm normalized name: MegaRed Kids Hello DHA Omega-3 Gummies (Watermelon and Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
Trial: NCT03813784
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Trial: NCT01855243
Drug: regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01855243
Drug: 70/30 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02905981
Drug: Shohl's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Trial: NCT02587598
Drug: I-DAC (Intermediate dose cytarabine)
RxNorm normalized name: Zodryl DAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
Trial: NCT01498432
Drug: Heliox21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
Trial: NCT00004465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00423384
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.v.
Trial: NCT03613649
Drug: AZD0914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
Trial: NCT02865720
Drug: CINRYZE 500 U
RxNorm normalized name: Cinryze 500 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion administered twice weekly
Trial: NCT03044964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
Trial: NCT02044991
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
Trial: NCT02044991
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo injection
Trial: NCT03661138
Drug: Topical Corticosteroids (TCS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is administered concomitantly with upadacitinib or placebo.
Trial: NCT02342886
Drug: HR (rifampicin plus isoniazid combination tablets)
RxNorm normalized name: Synovex H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01426971
Drug: IBUPROFEN + CAFFEINE
RxNorm normalized name: caffeine / ergotamine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule Route of administration: oral
Trial: NCT01426971
Drug: IBUPROFEN
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: capsule Route of administration: oral
Trial: NCT01148303
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
Trial: NCT01148303
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
Trial: NCT01148303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02064842
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
Trial: NCT02064842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily taken orally on Day 1 in Part 1
Trial: NCT02594904
Drug: Yinzhihuang Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the four groups will be given same treatment as being described in arm description.
Trial: NCT04631484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days